Raymond James raised the firm’s price target on Boston Scientific to $61 from $60 and keeps a Strong Buy rating on the shares. Boston Scientific’s Q2 results were worthy of a higher stock price as 12% organic revenue growth and 21% adjusted EPS growth is top-tier growth, especially for a company this size, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BSX:
- Boston Scientific price target raised to $61 from $57 at Needham
- Boston Scientific price target raised to $62 from $58 at Canaccord
- Boston Scientific price target raised to $59 from $58 at Oppenheimer
- Boston Scientific raises FY23 adjusted EPS view to $1.96-$2.00 from $1.90-$1.96
- Boston Scientific sees Q3 adjusted EPS 46c-48c, consensus 48c